Caution With Routine Use of Daratumumab for Newly Diagnosed High-Risk Multiple Myeloma

JAMA Oncol. 2021 Apr 1;7(4):635. doi: 10.1001/jamaoncol.2020.8008.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antibodies, Monoclonal / adverse effects
  • Bortezomib
  • Humans
  • Multiple Myeloma* / diagnosis
  • Multiple Myeloma* / drug therapy

Substances

  • Antibodies, Monoclonal
  • daratumumab
  • Bortezomib